Manish Dhanuka, Managing Director - Orchid Pharma gives insights on Orchid Pharma's partnership with Cipla. Orchid Pharma is looking to expand into the US Market.

#cipla #stockmarket #ndtvprofit 

For more videos subscribe to our channel: https://www.youtube.com/@NDTVProfitIndia
Visit NDTV Profit for more news: https://www.ndtvprofit.com/
Don't enter the stock market unaware. Read all Research Reports here: https://www.ndtvprofit.com/research-reports

Follow NDTV Profit here
Twitter: https://twitter.com/NDTVProfitIndia , https://twitter.com/NDTVProfit
LinkedIn: https://www.linkedin.com/company/ndtvprofit
Instagram: https://www.instagram.com/ndtvprofit/
Facebook: https://www.facebook.com/NDTVProfit/

Road Ahead For Orchid Pharma & Cipla's Partnership To Combat UTI I MD Manish Dhanuka Shares Outlook

The rise came following Orchid Pharma’s announcement of a collaboration with pharmaceutical giant Cipla to introduce the antibiotic Cefepime-Enmetazobactam in India

Orchid Pharma rises 4% on deal with Cipla to roll out new UTI drug in India

Orchid Pharma said that it has partnered with Cipla to ensure widespread and rapid distribution of the company’s new drug- Cefepime-Enmetazobactam across India.

Orchid Pharma partners with Cipla for pan-India distribution of Cefepime-Enmetazobactam

Orchid Pharma announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications.

Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India

Cipla partners with Orchid Pharma antibiotic: The partnership between Orchid Pharma and Cipla combines Orchid’s innovative drug development capabilities with Cipla’s extensive distribution network and market presence

Orchid Pharma join hands with Cipla to launch new antibiotic in India

We revise our target price on Orchid pharma at Rs. 1,057 as we raise our target price-to-earnings multiple from 30 times to 33 times.

Orchid Pharma - Enmetazobactam, First Indian NCE Gets U.S. FDA Nod: Systematix

Initiate coverage on Orchid Pharma with a ‘Buy’ rating and a target price of Rs 884, based on 30 times FY26E earnings per share.

Orchid Pharma - A Preferred Play On Import Substitution Opportunity: Systematix Initiates Coverage With A Buy

Backward integrating to key starting material - Commercialisation of seven-ACA manufacturing at Jammu to start in Q4 FY25.

Orchid Pharma - Opening Up Multiple Growth Avenues: Systematix

Orchid Pharma Consolidated June 2023 Net Sales at Rs 182.92 crore, up 39.65% Y-o-Y

Orchid Pharma meets SEBI’s MPS norms after QIP brings promoter stake below 75%. Raised ₹400cr in QIP, public shareholding now 27.6%. Mutual Funds hold 9.78%, FPI 8.58%, rest held by domestic corporates & retail investors. Stock down 4% to ₹590 on NSE.

Orchid Pharma meets SEBI’s minimum public shareholding norms

Orchid Pharma seeks shareholders’ approval to purchase key raw material from Otsuka Chemicals, a material subsidiary, up to ₹250 crore for FY24. The transaction is material as it exceeds ₹1,000 crore or 10% of the company’s annual turnover. Otsuka also buys the end product from Orchid under a long-t…

Orchid Pharma seeks shareholder nod for Otsuka Chemicals

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Orchid Pharma Limited, formerly Orchid Chemicals & Pharmaceuticals Limited, is a pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bulk actives, formulations and nutraceuticals.